Clinical Trials Directory
We are doing this study to identify patients who have gene changes or mutations in their tumor(s) and might be eligible for treatment using a combination of targeted therapy options. This study is called ComboMATCH (Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice).
Taking part in this study involves one visit that lasts about thirty minutes. During the visit, participants will answer a short survey about their health and hearing. They will also give a small saliva sample and have a gentle swab placed in the nose. These steps do not hurt. The visit can be done in person at a clinic or another location, or sometimes from home if the person lives nearby. There is no cost to take part, and there is no payment for joining the study.
We are doing this study to find out if a drug called pembrolizumab (the study drug) is a safe and effective option for people with undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. We want to know if adding it to treatment with the usual drug for this type of cancer can improve results.
This study has two parts. The first part tests different doses of a drug called EIS 12656 to learn about its safety and how the body handles it. The second part uses the best dose to study the drug in more people. You will be in the second part of the study. Doctors will do tests to see how your body and your cancer respond to the study drug. These tests may include physical exams, checking your vital signs, taking blood and urine samples, heart tests, scans, and tumor biopsies. You will also keep a diary to write down when you take the drug.
We are doing this study to test the safety and efficacy of elacestrant compared to standard of care therapy in people with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-) early breast cancer with a high risk of coming back. We want to compare the effect of elacestrant to standard of care therapy. We want to know which option is most helpful for patient in doing their normal day to day activities, and to assess what the study drug does to the tumor markers that can be measured in your blood.
In this study, people will get a special Medtronic pacemaker placed in their chest. This pacemaker uses special settings to test whether a pacing rate based on each person’s body and heart helps improve heart failure symptoms. After the device is placed, people are put into one of two groups by chance. One group gets personalized pacing based on their height and heart function. The other group gets very little pacing, used only as a backup if the heart rate drops too low. Most people and study staff will not know which group they are in during the first year so the results stay fair. People will return for checkups at 2, 6, 12, 14, 18, and 24 months, and then once a year. At these visits, they may have heart images, blood tests, ECGs, questionnaires, a six minute walk test, and pacemaker checks. After the 12 month visit, everyone in the group with minimal pacing will switch to personalized pacing, and the study will continue to check safety and benefits.
People in the study will get meals delivered to their homes from local groups. They’ll also agree to share what the experience was like for them.